Company intelligence / Profile preview

OVID Clinics

New York, New York, United States

Ownership: Private
Employees: ~42
Development stage: Other

Overview

OV329 Phase 1 topline results expected Q3 2025; OV350 safety/tolerability data anticipated Q4 2025; OV4071 IND-enabling package in progress with Phase 1/1b initiation planned Q2 2026

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

H. Lundbeck A/S (licensing agreement for OV101)Immedica Pharma AB (ganaxolone royalty monetization)

Beyond the preview

Go deeper on OVID Clinics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OVID Clinics.

Explore the full profile